
==== Front
Sci Rep
Sci Rep
Scientific Reports
2045-2322
Nature Publishing Group UK London

39300167
71881
10.1038/s41598-024-71881-7
Article
Genetically predicted frailty index and risk of chronic kidney disease
Chen Hui Juan 1
Qiu Jie qiujie1227@126.com

2
Guo Yihao 1
Chen Feng fenger0802@163.com

1
1 https://ror.org/030sr2v21 grid.459560.b 0000 0004 1764 5606 Department of Radiology, Hainan General Hospital (Hainan Affiliated Hospital of Hainan Medical University), No. 19, Xihua St., Xiuying Dis., Haikou, 570311 Hainan People’s Republic of China
2 https://ror.org/030sr2v21 grid.459560.b 0000 0004 1764 5606 Department of Ultrasound, Hainan General Hospital (Hainan Affiliated Hospital of Hainan Medical University), No. 19, Xihua St., Xiuying Dis., Haikou, 570311 Hainan People’s Republic of China
19 9 2024
19 9 2024
2024
14 2186225 3 2024
2 9 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Previous findings have reported the association between frailty and chronic kidney disease. However, the causality remains ambiguous. This study aimed to determine whether frailty index is causally associated with chronic kidney disease. We obtained the frailty genome-wide association study (GWAS) data and chronic kidney disease GWAS data from the FinnGen R5 (total n = 216,743; case = 3902, control = 212,841) as the exposure and outcome, respectively. A two-sample Mendelian randomization (MR) analysis was primarily conducted using the inverse-variance weighted (IVW), weighted median and MR-Egger regression analyses. Multivariable MR analysis (MVMR) was conducted for additional adjustment. In the two-sample Mendelian randomization analyses, a total of 14 single nucleotide polymorphisms (SNPs) were recognized as effective instrumental variables. The IVW method showed evidence to support a causal association between frailty index and chronic kidney disease (beta = 1.270; 95% CI 0.608 to 1.931; P < 0.001). MR-Egger revealed a causal association between frailty index and chronic kidney disease (beta = 3.612; 95% CI 0.805 to 6.419; P = 0.027). MR-Egger regression revealed that directional pleiotropy was unlikely to be biasing the result (intercept =  − 0.053; P = 0.119). The weighted median approach and weighted mode method also demonstrated a causal association between frailty index and chronic kidney disease (beta = 1.148; 95% CI 0.278 to 2.019; P = 0.011; beta = 2.194; 95% CI 0.598 to 3.790; P = 0.018). Cochran’s Q test and the funnel plot indicated no directional pleiotropy. MVMR analysis revealed that the causal association between frailty index and chronic kidney disease remained after adjusting for potential confounders, body-mass index, inflammatory bowel disease, waist-hip ratio, and C-reactive protein. Our study provides evidence of causal association between frailty and chronic kidney disease from genetic perspectives.

Keywords

Chronic kidney disease
Frailty
Mendelian randomization
Subject terms

Chronic kidney disease
Risk factors
the National Nature Science Foundation of China81801684 Chen Hui Juan Hainan Provincial Natural Science Foundation of China818MS124 Chen Hui Juan the Program of Hainan Association for Science and Technology Plans to Youth R & D InnovationQCXM201919 Chen Hui Juan the Hainan Province Clinical Medical Center and the innovation platform for Academicians of Hainan Provinceissue-copyright-statement© Springer Nature Limited 2024
==== Body
pmcIntroduction

Frailty is commonly characterized as a state resulting from diminished homeostatic reserves in an individual, leading to heightened susceptibility to stressors and a consequent increased likelihood of adverse health outcomes1. Frailty is becoming more prevalent with the aging population trend and is associated with various negative outcomes, including disability, hospitalization, chronic diseases, and increased mortality2–4. While a definitive gold standard for identifying frailty remains elusive, there is increasing focus on the frailty index (FI) as a potential key measure5. Comprehending the potential relationship between frailty and age-related diseases, along with the underlying mechanisms, could facilitate tailored management and early intervention strategies for frailty patients.

Chronic kidney disease (CKD), affecting approximately 10% of the worldwide population, posing a substantial challenge to global health systems due to its high mortality rate6–8. Frailty is very common among patients with CKD. A meta-analysis revealed a wide variation in frailty prevalence, ranging from 7% among community-dwelling individuals with CKD stages 1–4 as high as 73% in patients undergoing hemodialysis9. However, establishing a definitive causal relationship between frailty and CKD remains challenging, since observational studies may result in reverse causation or leave residual confounding factors unaddressed. The characteristics of the study population, sample size, and the covariates included in the regression models could also introduce potential biases into the research findings.

Mendelian Randomization (MR) is an approach in genetic epidemiology, utilizing summary-level data from genome-wide association studies (GWAS) to infer causal relationships between diverse exposures and their outcomes10. In MR analysis, genetic variants associated with the exposures of interest, while being independent of any confounding factors, serving as instrumental variables (IVs)10. Consequently, MR can alleviate issues related to reverse causation and confounding factors, offering valuable insights into the intrinsic relationship between frailty and CKD. This understanding carries substantial implications for both public health and clinical practice. A recent Genome-Wide Association Study (GWAS) has pinpointed 14 genetic loci that influence the Frailty Index (FI), a widely recognized definition of frailty11–13. The FI, based on the accumulation of health deficits, proves particularly effective in assessing frailty at its early stages. Previous study has found that FI is a significant predictor of hospitalization and mortality in nephrology14. However, limitations in sample size have constrained the statistical power of the study. This MR study aims to assessing the causal impacts of genetically predicted FI on the risk of developing CKD using the most comprehensive and extensive GWAS datasets available.

Materials and methods

Ethics approval

The study used publicly accessible GWAS data, ensuring compliance with ethical considerations as the requisite consents were obtained during the conduct of the original studies.

Instrumental variable selection for frailty index

The overall layout of this MR study is illustrated in Fig. 1. Genetic variants that are significantly associated with the FI (P < 5 × 10–8) were sourced from a comprehensive GWAS meta-analysis by Atkins et al.11. This meta-analysis incorporated data from a substantial cohort, including 164,610 participants from the UK Biobank and 10,616 participants from the TwinGene project11. All participants were of European ancestry. The FI was assessed using the “accumulation of deficits” model, a widely recognized approach in frailty research. This model quantifies frailty based on the number and severity of health deficits an individual has. In this case, the FI was calculated using more than 40 self-reported baseline deficit variables, encompassing various aspects of health and functioning11,15. The FI has been extensively validated and is recognized for its efficacy in predicting diverse adverse health outcomes and demonstrating a particular suitability for assessing frailty in younger populations. The meta-analysis of the GWAS has taken into account adjustments for factors such as age, sex, the study center, and the genotyping array used11.Fig. 1 Schematic overview of the study design. (A) The standard MR framework. MR relies on three core assumptions for causal inference: 1. the genetic variants should be related to the exposure (relevance assumption), 2. instrument variables should not be associated with confounders (independence assumption), 3. instrument variables affect the outcome through the exposure of interest only (exclusion restriction assumption, also known as the “no pleiotropy”). (B) Multivariable MR, an extension of univariable MR, utilizes genetic instruments associated with multiple correlated exposures to jointly assess the independent effect of each of the exposures on the outcome. MR Mendelian randomization.

Initially, 14 single nucleotide polymorphisms (SNPs) were selected (Supplementary Table 1). Subsequently, linkage disequilibrium analysis was conducted, resulting in the exclusion of SNPs with r2 > 0.01 and distance > 10,000 kb16. The F-statistic parameters, essential for determining the strength of the identified instrumental variables (IVs), were computed following previously established methodologies16,17. We excluded SNPs with an F-statistic parameter less than 10, as they were considered weak IVs. All 14 SNPs met the selection criteria and were thus incorporated into the MR analysis. In cases where a specific SNP was not available in the CKD datasets, a proxy SNP in linkage disequilibrium (r2 > 0.9) was utilized as a substitute.

CKD dataset

Summary statistics for the associations of the FI-related genetic variants with CKD were obtained from a GWAS dataset called finn-b-N14_CHRONKIDNEYDIS including 3902 cases and 212,841 controls.

Statistical analysis

For each SNP under examination, the Wald ratio we computed. Subsequently, these ratios were aggregated using the multiplicative random-effect inverse-variance weighted (IVW) method. This approach was employed to derive the MR estimates, facilitating a comprehensive assessment of the genetic associations18,19. The IVW method, in its essence, adopts a meta-analysis framework to aggregate Wald ratios from each genetic variant, thereby deriving combined estimates of the effect of exposure on outcomes. This method is particularly effective in delivering consistent causal estimates, assuming that all the genetic variants employed serve as valid IVs19. In addition to the IVW method, our analysis incorporated several supplementary approaches including MR-Egger, weighted mode, and weighted median18. The weighted mode method yields robust causal estimates under the condition that the weights linked to valid IVs are the most significant within any homogenous subset of instruments20. The weighted median method relies on identifying the estimate positioned at the 50th percentile of the empirical distribution, essentially representing the median of the weighted causal estimates21. To evaluate heterogeneity, Cochran’s Q test was conducted, and utilized the MR-Egger regression intercept and MRPRESSO to examine potential pleiotropy22,23. A leave-one-out analysis was carried out to determine whether any single SNP disproportionately influenced the estimated effect. Results were considered statistically significant at P < 0.05. The entirety of the MR analysis was executed using R software version 4.0.3 (R Foundation for Statistical Computing, Vienna, Austria) with the TwoSampleMR18 and MRPRESSO packages, along with Zstats v1.0 (www.zstats.net).

Multivariable MR and covariates

Previous study has found that the genetic association of body-mass index (BMI), inflammatory bowel disease (IBD), waist-hip ratio (WHR), and C-reactive protein (CRP) with the risk of frailty11. Therefore, these four variables were included in the multivariable MR analysis. The multivariable MR analysis (MVMR) incorporated genetic variants linked to at least one exposure, and the causal relationship was estimated using the multivariable IVW method20. BMI and WHR (adjusted for BMI) associated genetic variants were sourced from GIANT consortium24,25. IBD genetic variants were sourced from IIBDGC consortium26. Genetic variants associated with CRP were sourced from the study conducted by Said et al.27.

Results

Results of MR

Genetically predicted frailty index and risk of CKD

A total of 14 SNPs significantly associated with FI were included. IVW method indicated genetically predicted FI is associated with the increased risk of CKD (beta = 1.270; 95% CI 0.608 to 1.931; P < 0.001). Besides, MR-Egger analysis (beta = 3.612; 95% CI 0.805 to 6.419; P = 0.027), weighted median analysis (beta = 1.148, 95% CI 0.278 to 2.019; P = 0.097), and weighted mode analysis (beta = 2.193, 95% CI 0.598 to 3.790; P = 0.018) also indicated comparable results (Table 1, Figs. 2, 3). Table 1 MR results of frailty index and chronic kidney disease.

MR method	Number of SNPs	Beta	SE	95% confidence interval	P	
IVW	14	1.270	0.338	0.6081–1.9313	 < 0.001	
MR-Egger	14	3.612	1.432	0.8050–6.4193	0.027	
Weighted median	14	1.148	0.444	0.2776–2.0189	0.010	
Weighted mode	14	2.193	0.814	0.5980–3.7898	0.018	
IVW inverse-variance weighted, MR Mendelian randomization, SE standard error.

Fig. 2 Forest plot of the causal effects of SNP associated with frailty index on chronic kidney disease. The significance of red lines is MR results of MR-Egger test and IVW method. SNP single nucleotide polymorphism, MR Mendelian randomization.

Fig. 3 Scatter plots of genetic associations with frailty index against the genetic associations with chronic kidney disease. The slopes of each line represent the causal association for each method. The blue line represents the IVW estimate, the green line represents the weighted median estimate, the dark blue line represents the MR‐Egger estimate, the dark green line represents weighted mode. IVW inverse-variance weighted, MR Mendelian randomization.

Sensitivity analysis indicated no heterogeneities (all P > 0.050) in the estimated effects of FI on CKD. MR-Egger regression analysis discovered that directional pleiotropy did not introduce significant bias to the results, with an intercept of − 0.053 (P = 0.119). Furthermore, MR-PRESSO results suggested that there was no evidence of horizontal pleiotropy in this MR study (P = 0.240). Additionally, the result of a leave-one-out analysis affirmed the reliability of estimated effects across varying SNP exclusions (Fig. 4). Altogether, the present MR analysis suggested the association between genetically predicted FI and the risk of any CKD at a significance level of one standard.Fig. 4 “Leave-one-out” analysis examining the causal between frailty index and chronic kidney disease. Each black dot and bar represent the causal estimate and its 95% confidence interval (CI) when an individual SNP is sequentially excluded. The red dot and bar indicate the overall estimate and 95% CI; CI confidence interval, SNP single nucleotide polymorphism, IVW inverse-variance weighted.

Multivariable Mendelian randomisation analysis

We conducted a MVMR analysis that included BMI, CRP, WHR (adjusted for BMI), and IBD as covariates to further assess the causal relationships between genetic predictions of the FI and the risks of CKD. MVMR results demonstrated that the direct causal effect of FI on CKD was still significant after adjusting for BMI (OR 2.408, 95% CI 1.135 to 5.107, P = 0.022), WHR (adjusted for BMI) (OR 2.686, 95% CI 1.090–6.617, P = 0.032), IBD (OR 4.531, 95% CI 1.897 to 10.823, P < 0.001), and CRP (OR 1.855, 95% CI 1.011 to 3.404, P = 0.046) (Fig. 5).Fig. 5 Multivariable mendelian randomisation analysis of the association between genetically predicted frailty index and risk of chronic kidney disease. BMI body-mass index, CRP C-reactive protein, IBD inflammatory bowel disease, WHR waist-hip ratio.

Discussion

To our knowledge, this is the first study to investigate the association between FI and CKD. The FI is widely recognized as a prognostic indicator of adverse outcomes in CKD. However, the causal relationship between FI and CKD remains unanswered. In the present study, we employed four distinct methodologies for MR analysis: the IVW approach, the weighted median method, the MR-egger regression test, and the weighted mode technique. Each method independently pointed towards a positive causal relationship between FI and CKD. After adjusting for BMI, CRP, IBD, and WHR (adjusted for BMI), the effect of genetically predicted FI on CKD remained significant. Consequently, our findings substantiate the hypothesis that FI is causally linked to the progression of CKD.

Frailty is characterized by an increased vulnerability to health issues and affects approximately 1 in 6 older individuals residing in communities28. Frailty heightens the probability of negative consequences such as falls, hospital admissions, disability, and mortality29,30. The conceptual framework of FI posits frailty as a process of accumulating deficits, starting at the cellular level and resulting in diminished organ system redundancy31. The FI, a widely adopted tool in clinical settings for assessing frailty, has been thoroughly validated in numerous previous studies30,32.

In patients before dialysis, the prevalence of frailty varied between 7 and 42.6%33,34. The prevalence of frailty in patients undergoing hemodialysis could be even higher, potentially reaching as high as 73%35. Patients suffering from CKD and exhibiting frailty faced an increased risk of both mortality and hospitalization. The risk of mortality was notably high among patients with CKD, affecting those both on dialysis and in the pre-dialysis stage35–38. In comparison to non-frail CKD patients, frailty patients almost double the risk of medically urgent falls or fractures39. Additionally, previous study reported that frail CKD undergoing dialysis faced a 2.6 times higher risk of mortality40. In a recent meta-analysis, patients with frailty exhibited an increased risk of all-cause mortality compared to their non-frail counterparts41. Moreover, frail individuals on hemodialysis exhibit an elevated risk of hospital admissions and morality42. Hence, it is essential to offer prompt psychological support and guidance to frail patients.

Several mechanisms have been suggested to explain the relationship between frailty and CKD. A study involving the National Health and Nutrition Examination Survey found that frailty is associated with a significantly higher risk of CKD across all stages, even in individuals with preserved kidney function (eGFR > 60 mL/min/1.73 m2)43. This suggests that frailty may be a risk factor for the development of CKD, rather than just a consequence of existing kidney disease. Frailty, characterized by multi-system impairment including inflammation, immune dysfunction, and metabolic dysregulation, shares common pathways with the development of CKD44. These biological mechanisms contribute to the increased susceptibility of frail individuals to kidney damage, supporting the idea that frailty can lead to the inception of CKD. Several studies have uncovered the relationships between measures of kidney function and frailty45–47. A study by the Atherosclerosis Risk in Communities group revealed an association between frailty and decreases in cystatin C-based estimated glomerular filtration rate45. Dalrymple et al. found that lower estimated glomerular filtration rate calculated using serum cystatin C (eGFRcys) correlated with an increased risk of both existing and developing frailty46. In a recent cohort study, Li et al. found that Cystatin C and eGFRcys were associated with trajectories of frailty in the long run47. Besides, chronic inflammation may also play an important role in frailty development. Extant research indicates that inflammation is related to frailty across various chronic diseases, suggesting a ‘shared pathophysiology’ underlying frailty31. Elevated levels of inflammatory markers including C-reactive protein, interleukin-6, and tumor necrosis factor are associated with frailty48,49. Besides, CKD patients exhibit increased levels of proinflammatory cytokines50. Therefore, chronic inflammation is a well-recognized common pathway contributing to both frailty and CKD. However, frailty may independently contribute to the worsening of CKD through several mechanisms. Firstly, frailty is associated with a catabolic state and muscle wasting51, leading to decreased renal function and increased risk of CKD progression. Secondly, frailty often coincides with malnutrition and reduced protein intake, which can adversely affect renal function. Thirdly, frailty is linked to cardiovascular dysfunction52, which can lead to decreased renal perfusion and contribute to CKD. Fourthly, chronic low-grade inflammation is common in frailty and can exacerbate CKD through mechanisms like endothelial dysfunction and fibrosis.

Several limitations should be mentioned in this study. First, the issue of population stratification stands as a potential biasing factor in the MR analysis, given the observed tendency for older frailty patients and predominantly female53. Secondly, the presence of pleiotropy, especially horizontal pleiotropy, is an almost inescapable aspect of MR analysis. Although the MR-Egger intercept test was conducted to mitigate horizontal pleiotropy, complete mitigation remains challenging. Thirdly, the relatively low adoption rate poses the limitation, particularly in countries with low or middle income, where FI utilization is not widespread. Moreover, prior studies have indicated a higher probability of frailty among individuals with lower socioeconomic status. However, the reliance on GWAS data for FI predominantly derived from the UK Biobank may introduce selection bias. This is because individuals with lower socioeconomic status, who are more likely to exhibit frailty, may be underrepresented in the UK Biobank. Additionally, participants in the UK Biobank tend to be healthier than the general population, which could skew our findings towards a healthier demographic. Fourthly, our study relies on cross-sectional data, which limits the ability to assess the temporal relationship between FI and CKD. Future research should involve longitudinal data to better capture the temporal dynamics between FI and CKD. Besides, the inclusion of only individuals of European populations limits the generalizability of the findings to other ethnic groups. We will extend our research to include diverse ethnic populations in future studies to enhance the applicability of our findings globally. Fifth, while the study establishes a causal relationship between FI and CKD, it does not provide insights into the underlying biological mechanisms. We will integrate additional omics data (e.g., transcriptomics, proteomics) in future studies to help elucidate the molecular pathways involved. We are also considering collaborations with experts in the field of systems biology and bioinformatics to ensure a multidisciplinary approach to dissecting these complex mechanisms. Last but not least, we did not replicate our results in an independent cohort due to resource constraint. We plan to collaborate with other research groups to access independent cohorts for replication studies.

In conclusion, this MR analysis supported that genetically predicted FI is probably associated with an increased risk of CKD. Our results suggest that FI may play an important role in the development of CKD. The findings might offer a chance to explore the mechanisms of FI on the development of CKD.

Supplementary Information

Supplementary Table 1.

Supplementary Information

The online version contains supplementary material available at 10.1038/s41598-024-71881-7.

Acknowledgements

The authors thank all the investigators of corresponding genetic consortia and GWAS for providing the data publicly.

Author contributions

Hui Juan Chen and Jie Qiu led the analysis and writing of this paper. All authors read and contributed to the drafting of the paper. Yihao Guo did the interpretation of the data. Feng Chen conceived and designed the experiment. All authors reviewed the manuscript and approved the publication of our manuscript.

Funding

This work was supported by the Hainan Province 'Nanhai Rising Star' Healthcare Talent Platform Project (NHXX-WJW-2023003), the Key Science and Technology Project of Hainan Province (ZDYF2024SHFZ058), the National Nature Science Foundation of China [Grant Numbers 82271977; 81971602; 82160327; 82160327; 81801684], Hainan Medical University Undergraduate Innovation and Entrepreneurship Training Program (X202311810019), and the Program of Hainan Association for Science and Technology Plans to Youth R & D Innovation (QCXM201919). This project was supported by the Key Science and Technology Project of Hainan Province (ZDYF2021SHFZ239,  ZDYF2021SHFZ246), the Hainan Academician Innovation Platform Fund, and the Hainan Province Clinical Medical Center.

Data availability

The datasets analyzed in the current study are publicly available from the public datasets (https://gwas.mrcieu.ac.uk/datasets/ebi-a-GCST90020053/ for ebi-a-GCST90020053 and https://gwas.mrcieu.ac.uk/datasets/finn-b-N14_CHRONKIDNEYDIS/ for finn-b-N14_CHRONKIDNEYDIS).

Competing interests

The authors declare no competing interests.

Ethical approval

The included genome-wide association studies (GWASs) had obtained the necessary ethical approvals from the relevant committees and written informed consent was obtained from all individuals involved in these studies. This study based on the summary-level data requires no ethical permit.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Buta BJ Walston JD Godino JG Frailty assessment instruments: Systematic characterization of the uses and contexts of highly-cited instruments Ageing Res. Rev. 2016 26 53 61 10.1016/j.arr.2015.12.003 26674984
Buta, B. J. et al. Frailty assessment instruments: Systematic characterization of the uses and contexts of highly-cited instruments. Ageing Res. Rev. 26, 53–61 (2016).26674984
2. Veronese N Custodero C Cella A Prevalence of multidimensional frailty and pre-frailty in older people in different settings: A systematic review and meta-analysis Ageing Res. Rev. 2021 72 101498 10.1016/j.arr.2021.101498 34700009
Veronese, N. et al. Prevalence of multidimensional frailty and pre-frailty in older people in different settings: A systematic review and meta-analysis. Ageing Res. Rev. 72, 101498 (2021).34700009
3. Evans NR Todd OM Minhas JS Frailty and cerebrovascular disease: Concepts and clinical implications for stroke medicine Int. J. Stroke 2022 17 3 251 259 10.1177/17474930211034331 34282986
Evans, N. R. et al. Frailty and cerebrovascular disease: Concepts and clinical implications for stroke medicine. Int. J. Stroke 17(3), 251–259 (2022).34282986
4. Tan LF Lim ZY Choe R Seetharaman S Merchant R Screening for frailty and sarcopenia among older persons in medical outpatient clinics and its associations with healthcare burden J. Am. Med. Dir. Assoc. 2017 18 7 583 587 10.1016/j.jamda.2017.01.004 28242192
Tan, L. F., Lim, Z. Y., Choe, R., Seetharaman, S. & Merchant, R. Screening for frailty and sarcopenia among older persons in medical outpatient clinics and its associations with healthcare burden. J. Am. Med. Dir. Assoc. 18(7), 583–587 (2017).28242192
5. Rockwood K Song X MacKnight C A global clinical measure of fitness and frailty in elderly people Can. Med. Assoc. J. 2005 173 5 489 495 10.1503/cmaj.050051 16129869
Rockwood, K. et al. A global clinical measure of fitness and frailty in elderly people. Can. Med. Assoc. J. 173(5), 489–495 (2005).16129869
6. Vos T Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016 Lancet 2017 390 10100 1211 1259 10.1016/S0140-6736(17)32154-2 28919117
Vos, T. et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet 390(10100), 1211–1259 (2017).28919117
7. Woo KT Choong HL Wong KS Tan HB Chan CM The contribution of chronic kidney disease to the global burden of major noncommunicable diseases Kidney Int. 2012 81 10 1044 1045 10.1038/ki.2012.39 22543907
Woo, K. T., Choong, H. L., Wong, K. S., Tan, H. B. & Chan, C. M. The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int. 81(10), 1044–1045 (2012).22543907
8. Ene-Iordache B Perico N Bikbov B Chronic kidney disease and cardiovascular risk in six regions of the world (ISN-KDDC): A cross-sectional study Lancet Glob. Health 2016 4 5 e307 e319 10.1016/S2214-109X(16)00071-1 27102194
Ene-Iordache, B. et al. Chronic kidney disease and cardiovascular risk in six regions of the world (ISN-KDDC): A cross-sectional study. Lancet Glob. Health 4(5), e307–e319 (2016).27102194
9. Li BH Sang N Zhang MY The prevalence and influencing factors of frailty in patients with chronic kidney disease: A systematic review and meta-analysis Int. Urol. Nephrol. 2023 56 767 10.1007/s11255-023-03739-2 37578673
Li, B. H. et al. The prevalence and influencing factors of frailty in patients with chronic kidney disease: A systematic review and meta-analysis. Int. Urol. Nephrol. 56, 767 (2023).37578673
10. Lawlor DA Harbord RM Sterne JA Timpson N Davey SG Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology Stat. Med. 2008 27 8 1133 1163 10.1002/sim.3034 17886233
Lawlor, D. A., Harbord, R. M., Sterne, J. A., Timpson, N. & Davey, S. G. Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology. Stat. Med. 27(8), 1133–1163 (2008).17886233
11. Atkins JL Jylhävä J Pedersen NL A genome-wide association study of the frailty index highlights brain pathways in ageing Aging Cell 2021 20 9 e13459 10.1111/acel.13459 34431594
Atkins, J. L. et al. A genome-wide association study of the frailty index highlights brain pathways in ageing. Aging Cell 20(9), e13459 (2021).34431594
12. Blodgett J Theou O Kirkland S Andreou P Rockwood K Frailty in NHANES: Comparing the frailty index and phenotype Arch. Gerontol. Geriatr. 2015 60 3 464 470 10.1016/j.archger.2015.01.016 25697060
Blodgett, J., Theou, O., Kirkland, S., Andreou, P. & Rockwood, K. Frailty in NHANES: Comparing the frailty index and phenotype. Arch. Gerontol. Geriatr. 60(3), 464–470 (2015).25697060
13. Liu W Zhang L Fang H Genetically predicted frailty index and risk of stroke and Alzheimer's disease Eur. J. Neurol. 2022 29 7 1913 1921 10.1111/ene.15332 35318774
Liu, W. et al. Genetically predicted frailty index and risk of stroke and Alzheimer’s disease. Eur. J. Neurol. 29(7), 1913–1921 (2022).35318774
14. Vezza C Vettoretti S Caldiroli L Bergamaschini L Messa P Cesari M Use of the frailty index in older persons with chronic kidney disease J. Am. Med. Dir. Assoc. 2019 20 9 1179 1180 10.1016/j.jamda.2019.04.015 31176674
Vezza, C. et al. Use of the frailty index in older persons with chronic kidney disease. J. Am. Med. Dir. Assoc. 20(9), 1179–1180 (2019).31176674
15. Mitnitski AB Mogilner AJ Rockwood K Accumulation of deficits as a proxy measure of aging Sci. World J. 2001 1 323 336 10.1100/tsw.2001.58
Mitnitski, A. B., Mogilner, A. J. & Rockwood, K. Accumulation of deficits as a proxy measure of aging. Sci. World J. 1, 323–336 (2001).
16. Burgess S Thompson SG Avoiding bias from weak instruments in Mendelian randomization studies Int. J. Epidemiol. 2011 40 3 755 764 10.1093/ije/dyr036 21414999
Burgess, S. & Thompson, S. G. Avoiding bias from weak instruments in Mendelian randomization studies. Int. J. Epidemiol. 40(3), 755–764 (2011).21414999
17. Burgess S Small DS Thompson SG A review of instrumental variable estimators for Mendelian randomization Stat. Methods Med. Res. 2017 26 5 2333 2355 10.1177/0962280215597579 26282889
Burgess, S., Small, D. S. & Thompson, S. G. A review of instrumental variable estimators for Mendelian randomization. Stat. Methods Med. Res. 26(5), 2333–2355 (2017).26282889
18. Hemani G Zheng J Elsworth B The MR-Base platform supports systematic causal inference across the human phenome eLife 2018 7 8 10.7554/eLife.34408
Hemani, G. et al. The MR-Base platform supports systematic causal inference across the human phenome. eLife 7, 8 (2018).
19. Burgess S Butterworth A Thompson SG Mendelian randomization analysis with multiple genetic variants using summarized data Genet. Epidemiol. 2013 37 7 658 665 10.1002/gepi.21758 24114802
Burgess, S., Butterworth, A. & Thompson, S. G. Mendelian randomization analysis with multiple genetic variants using summarized data. Genet. Epidemiol. 37(7), 658–665 (2013).24114802
20. Burgess S Thompson SG Multivariable Mendelian randomization: The use of pleiotropic genetic variants to estimate causal effects Am. J. Epidemiol. 2015 181 4 251 260 10.1093/aje/kwu283 25632051
Burgess, S. & Thompson, S. G. Multivariable Mendelian randomization: The use of pleiotropic genetic variants to estimate causal effects. Am. J. Epidemiol. 181(4), 251–260 (2015).25632051
21. Burgess S Bowden J Fall T Ingelsson E Thompson SG Sensitivity analyses for robust causal inference from Mendelian randomization analyses with multiple genetic variants Epidemiology 2017 28 1 30 42 10.1097/EDE.0000000000000559 27749700
Burgess, S., Bowden, J., Fall, T., Ingelsson, E. & Thompson, S. G. Sensitivity analyses for robust causal inference from Mendelian randomization analyses with multiple genetic variants. Epidemiology 28(1), 30–42 (2017).27749700
22. Bowden J Del Greco MF Minelli C Davey Smith G Sheehan NA Thompson JR Assessing the suitability of summary data for two-sample Mendelian randomization analyses using MR-Egger regression: The role of the I2 statistic Int. J. Epidemiol. 2016 45 6 1961 1974 27616674
Bowden, J. et al. Assessing the suitability of summary data for two-sample Mendelian randomization analyses using MR-Egger regression: The role of the I2 statistic. Int. J. Epidemiol. 45(6), 1961–1974 (2016).27616674
23. Higgins JP Thompson SG Quantifying heterogeneity in a meta-analysis Stat. Med. 2002 21 11 1539 1558 10.1002/sim.1186 12111919
Higgins, J. P. & Thompson, S. G. Quantifying heterogeneity in a meta-analysis. Stat. Med. 21(11), 1539–1558 (2002).12111919
24. Locke AE Kahali B Berndt SI Genetic studies of body mass index yield new insights for obesity biology Nature 2015 518 7538 197 206 10.1038/nature14177 25673413
Locke, A. E. et al. Genetic studies of body mass index yield new insights for obesity biology. Nature 518(7538), 197–206 (2015).25673413
25. Shungin D Winkler TW Croteau-Chonka DC New genetic loci link adipose and insulin biology to body fat distribution Nature 2015 518 7538 187 196 10.1038/nature14132 25673412
Shungin, D. et al. New genetic loci link adipose and insulin biology to body fat distribution. Nature 518(7538), 187–196 (2015).25673412
26. Liu JZ van Sommeren S Huang H Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations Nat. Genet. 2015 47 9 979 986 10.1038/ng.3359 26192919
Liu, J. Z. et al. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat. Genet. 47(9), 979–986 (2015).26192919
27. Said S Pazoki R Karhunen V Genetic analysis of over half a million people characterises C-reactive protein loci Nat. Commun. 2022 13 1 2198 10.1038/s41467-022-29650-5 35459240
Said, S. et al. Genetic analysis of over half a million people characterises C-reactive protein loci. Nat. Commun. 13(1), 2198 (2022).35459240
28. Ofori-Asenso R Chin KL Mazidi M Global incidence of frailty and prefrailty among community-dwelling older adults: A systematic review and meta-analysis JAMA Netw. Open 2019 2 8 e198398 10.1001/jamanetworkopen.2019.8398 31373653
Ofori-Asenso, R. et al. Global incidence of frailty and prefrailty among community-dwelling older adults: A systematic review and meta-analysis. JAMA Netw. Open 2(8), e198398 (2019).31373653
29. Walston J Buta B Xue QL Frailty screening and interventions: Considerations for clinical practice Clin. Geriatr. Med. 2018 34 1 25 38 10.1016/j.cger.2017.09.004 29129215
Walston, J., Buta, B. & Xue, Q. L. Frailty screening and interventions: Considerations for clinical practice. Clin. Geriatr. Med. 34(1), 25–38 (2018).29129215
30. Hoogendijk EO Afilalo J Ensrud KE Kowal P Onder G Fried LP Frailty: Implications for clinical practice and public health Lancet 2019 394 10206 1365 1375 10.1016/S0140-6736(19)31786-6 31609228
Hoogendijk, E. O. et al. Frailty: Implications for clinical practice and public health. Lancet 394(10206), 1365–1375 (2019).31609228
31. Jeffery CA Shum DW Hubbard RE Emerging drug therapies for frailty Maturitas 2013 74 1 21 25 10.1016/j.maturitas.2012.10.010 23141547
Jeffery, C. A., Shum, D. W. & Hubbard, R. E. Emerging drug therapies for frailty. Maturitas 74(1), 21–25 (2013).23141547
32. Dent E Kowal P Hoogendijk EO Frailty measurement in research and clinical practice: A review Eur. J. Intern. Med. 2016 31 3 10 10.1016/j.ejim.2016.03.007 27039014
Dent, E., Kowal, P. & Hoogendijk, E. O. Frailty measurement in research and clinical practice: A review. Eur. J. Intern. Med. 31, 3–10 (2016).27039014
33. Reese PP Cappola AR Shults J Physical performance and frailty in chronic kidney disease Am. J. Nephrol. 2013 38 4 307 315 10.1159/000355568 24107579
Reese, P. P. et al. Physical performance and frailty in chronic kidney disease. Am. J. Nephrol. 38(4), 307–315 (2013).24107579
34. Mansur HN Colugnati FA Grincenkov FR Bastos MG Frailty and quality of life: A cross-sectional study of Brazilian patients with pre-dialysis chronic kidney disease Health Qual. Life Outcomes 2014 12 27 10.1186/1477-7525-12-27 24580960
Mansur, H. N., Colugnati, F. A., Grincenkov, F. R. & Bastos, M. G. Frailty and quality of life: A cross-sectional study of Brazilian patients with pre-dialysis chronic kidney disease. Health Qual. Life Outcomes 12, 27 (2014).24580960
35. Bao Y Dalrymple L Chertow GM Kaysen GA Johansen KL Frailty, dialysis initiation, and mortality in end-stage renal disease Arch. Intern. Med. 2012 172 14 1071 1077 10.1001/archinternmed.2012.3020 22733312
Bao, Y., Dalrymple, L., Chertow, G. M., Kaysen, G. A. & Johansen, K. L. Frailty, dialysis initiation, and mortality in end-stage renal disease. Arch. Intern. Med. 172(14), 1071–1077 (2012).22733312
36. Pugh J Aggett J Goodland A Frailty and comorbidity are independent predictors of outcome in patients referred for pre-dialysis education Clin. Kidney J. 2016 9 2 324 329 10.1093/ckj/sfv150 26985387
Pugh, J. et al. Frailty and comorbidity are independent predictors of outcome in patients referred for pre-dialysis education. Clin. Kidney J. 9(2), 324–329 (2016).26985387
37. King SJ Reid N Brown SJ A prospective, observational study of frailty, quality of life and dialysis in older people with advanced chronic kidney disease BMC Geriatr. 2023 23 1 664 10.1186/s12877-023-04365-4 37845618
King, S. J. et al. A prospective, observational study of frailty, quality of life and dialysis in older people with advanced chronic kidney disease. BMC Geriatr. 23(1), 664 (2023).37845618
38. Alfaadhel TA Soroka SD Kiberd BA Landry D Moorhouse P Tennankore KK Frailty and mortality in dialysis: Evaluation of a clinical frailty scale Clin. J. Am. Soc. Nephrol. 2015 10 5 832 840 10.2215/CJN.07760814 25739851
Alfaadhel, T. A. et al. Frailty and mortality in dialysis: Evaluation of a clinical frailty scale. Clin. J. Am. Soc. Nephrol. 10(5), 832–840 (2015).25739851
39. Delgado C Shieh S Grimes B Association of self-reported frailty with falls and fractures among patients new to dialysis Am. J. Nephrol. 2015 42 2 134 140 10.1159/000439000 26381744
Delgado, C. et al. Association of self-reported frailty with falls and fractures among patients new to dialysis. Am. J. Nephrol. 42(2), 134–140 (2015).26381744
40. McAdams-DeMarco MA Law A Salter ML Frailty as a novel predictor of mortality and hospitalization in individuals of all ages undergoing hemodialysis J. Am. Geriatr. Soc. 2013 61 6 896 901 10.1111/jgs.12266 23711111
McAdams-DeMarco, M. A. et al. Frailty as a novel predictor of mortality and hospitalization in individuals of all ages undergoing hemodialysis. J. Am. Geriatr. Soc. 61(6), 896–901 (2013).23711111
41. Lee HJ, Son YJ. Prevalence and associated factors of frailty and mortality in patients with end-stage renal disease undergoing hemodialysis: A systematic review and meta-analysis. Int. J. Environ. Res. Public Health 2021;18(7), 3471.
42. Soldati A Poggi MM Azzolino D Vettoretti S Cesari M Frailty index and adverse outcomes in older patients in haemodialysis Arch. Gerontol. Geriatr. 2022 101 104673 10.1016/j.archger.2022.104673 35272204
Soldati, A., Poggi, M. M., Azzolino, D., Vettoretti, S. & Cesari, M. Frailty index and adverse outcomes in older patients in haemodialysis. Arch. Gerontol. Geriatr. 101, 104673 (2022).35272204
43. Wilhelm-Leen ER Hall YN Tamura MK Chertow GM Frailty and chronic kidney disease: The Third National Health and Nutrition Evaluation Survey Am. J. Med. 2009 122 7 664 671 10.1016/j.amjmed.2009.01.026 19559169
Wilhelm-Leen, E. R., Hall, Y. N., Tamura, M. K. & Chertow, G. M. Frailty and chronic kidney disease: The Third National Health and Nutrition Evaluation Survey. Am. J. Med. 122(7), 664–671 (2009).19559169
44. Lorenz EC Kennedy CC Rule AD LeBrasseur NK Kirkland JL Hickson LJ Frailty in CKD and transplantation Kidney Int. Rep. 2021 6 9 2270 2280 10.1016/j.ekir.2021.05.025 34514190
Lorenz, E. C. et al. Frailty in CKD and transplantation. Kidney Int. Rep. 6(9), 2270–2280 (2021).34514190
45. Ballew SH Chen Y Daya NR Frailty, kidney function, and polypharmacy: The atherosclerosis risk in communities (ARIC) study Am. J. Kidney Dis. 2017 69 2 228 236 10.1053/j.ajkd.2016.08.034 27884475
Ballew, S. H. et al. Frailty, kidney function, and polypharmacy: The atherosclerosis risk in communities (ARIC) study. Am. J. Kidney Dis. 69(2), 228–236 (2017).27884475
46. Dalrymple LS Katz R Rifkin DE Kidney function and prevalent and incident frailty Clin. J. Am. Soc. Nephrol. 2013 8 12 2091 2099 10.2215/CJN.02870313 24178972
Dalrymple, L. S. et al. Kidney function and prevalent and incident frailty. Clin. J. Am. Soc. Nephrol. 8(12), 2091–2099 (2013).24178972
47. Li C Ma Y Yang C Hua R Xie W Zhang L Association of cystatin C kidney function measures with long-term deficit-accumulation frailty trajectories and physical function decline JAMA Netw. Open 2022 5 9 e2234208 10.1001/jamanetworkopen.2022.34208 36178684
Li, C. et al. Association of cystatin C kidney function measures with long-term deficit-accumulation frailty trajectories and physical function decline. JAMA Netw. Open 5(9), e2234208 (2022).36178684
48. Soysal P Stubbs B Lucato P Inflammation and frailty in the elderly: A systematic review and meta-analysis Ageing Res. Rev. 2016 31 1 8 10.1016/j.arr.2016.08.006 27592340
Soysal, P. et al. Inflammation and frailty in the elderly: A systematic review and meta-analysis. Ageing Res. Rev. 31, 1–8 (2016).27592340
49. Nascimento CMC Zazzetta MS Gomes GAO Higher levels of tumor necrosis factor β are associated with frailty in socially vulnerable community-dwelling older adults BMC Geriatr. 2018 18 1 268 10.1186/s12877-018-0961-6 30400833
Nascimento, C. M. C. et al. Higher levels of tumor necrosis factor β are associated with frailty in socially vulnerable community-dwelling older adults. BMC Geriatr. 18(1), 268 (2018).30400833
50. Chowdhury R Peel NM Krosch M Hubbard RE Frailty and chronic kidney disease: A systematic review Arch. Gerontol. Geriatr. 2017 68 135 142 10.1016/j.archger.2016.10.007 27810661
Chowdhury, R., Peel, N. M., Krosch, M. & Hubbard, R. E. Frailty and chronic kidney disease: A systematic review. Arch. Gerontol. Geriatr. 68, 135–142 (2017).27810661
51. Kennard AL Glasgow NJ Rainsford SE Talaulikar GS Narrative review: Clinical implications and assessment of frailty in patients with advanced CKD Kidney Int. Rep. 2024 9 4 791 806 10.1016/j.ekir.2023.12.022 38765572
Kennard, A. L., Glasgow, N. J., Rainsford, S. E. & Talaulikar, G. S. Narrative review: Clinical implications and assessment of frailty in patients with advanced CKD. Kidney Int. Rep. 9(4), 791–806 (2024).38765572
52. He D Wang Z Li J Changes in frailty and incident cardiovascular disease in three prospective cohorts Eur. Heart J. 2024 45 12 1058 1068 10.1093/eurheartj/ehad885 38241094
He, D. et al. Changes in frailty and incident cardiovascular disease in three prospective cohorts. Eur. Heart J. 45(12), 1058–1068 (2024).38241094
53. Damluji AA Chung SE Xue QL Frailty and cardiovascular outcomes in the National Health and Aging Trends Study Eur. Heart J. 2021 42 37 3856 3865 10.1093/eurheartj/ehab468 34324648
Damluji, A. A. et al. Frailty and cardiovascular outcomes in the National Health and Aging Trends Study. Eur. Heart J. 42(37), 3856–3865 (2021).34324648
